TB006, a humanized IgG4 monoclonal antibody targeting Gal-3, is positioned to address core symptoms of Autism Spectrum Disorder (ASD) in adults. The market for ASD treatments is expanding, with increasing recognition of the need for effective therapies. Given the unique mechanism of action targeting neuroinflammation, TB006 may differentiate itself from existing therapies. The trial's design, including a 14-week open-label extension, suggests a commitment to understanding long-term efficacy and safety, which could enhance market acceptance. The collaboration with the Autism Discovery and Treatment Foundation may bolster credibility and facilitate patient recruitment. However, the competitive landscape includes other emerging therapies targeting similar pathways, necessitating ongoing diligence to assess TB006's positioning and potential market share.